Charles Schwab’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $745K | Sell |
120,514
-6,595
| -5% | -$36.2K | ﹤0.01% | 3108 |
|
|
2026
Q1 | $569K | Sell |
127,109
-5,794
| -4% | -$29K | ﹤0.01% | 3068 |
|
|
2025
Q4 | $700K | Sell |
132,903
-657
| -0.5% | -$3.31K | ﹤0.01% | 3047 |
|
|
2025
Q3 | $705K | Sell |
133,560
-792
| -0.6% | -$5.02K | ﹤0.01% | 3062 |
|
|
2025
Q2 | $763K | Buy |
134,352
+109,895
| +449% | +$626K | ﹤0.01% | 2988 |
|
|
2025
Q1 | $116K | Buy |
24,457
+607
| +3% | +$3.3K | ﹤0.01% | 3316 |
|
|
2024
Q4 | $133K | Hold |
23,850
| – | – | ﹤0.01% | 3372 |
|
|
2024
Q3 | $151K | Buy |
+23,850
| New | +$125K | ﹤0.01% | 3357 |
|
|
2023
Q2 | – | Sell |
-18,000
| Closed | -$50.8K | – | 3610 |
|
|
2023
Q1 | $50.8K | Buy |
+18,000
| New | +$47.1K | ﹤0.01% | 3346 |
|
|
2022
Q1 | – | Sell |
-1,411
| Closed | -$12K | – | 3581 |
|
|
2021
Q4 | $12K | Hold |
1,411
| – | – | ﹤0.01% | 3588 |
|
|
2021
Q3 | $40K | Hold |
1,411
| – | – | ﹤0.01% | 3471 |
|
|
2021
Q2 | $56K | Sell |
1,411
-5,141
| -78% | -$210K | ﹤0.01% | 3352 |
|
|
2021
Q1 | $308K | Buy |
6,552
+761
| +13% | +$41.9K | ﹤0.01% | 3235 |
|
|
2020
Q4 | $228K | Hold |
5,791
| – | – | ﹤0.01% | 3238 |
|
|
2020
Q3 | $148K | Hold |
5,791
| – | – | ﹤0.01% | 3220 |
|
|
2020
Q2 | $423K | Sell |
5,791
-215
| -4% | -$14.9K | ﹤0.01% | 2899 |
|
|
2020
Q1 | $316K | Buy |
6,006
+2,895
| +93% | +$193K | ﹤0.01% | 2874 |
|
|
2019
Q4 | $255K | Hold |
3,111
| – | – | ﹤0.01% | 3007 |
|
|
2019
Q3 | $176K | Hold |
3,111
| – | – | ﹤0.01% | 3055 |
|
|
2019
Q2 | $372K | Buy |
3,111
+372
| +14% | +$62.4K | ﹤0.01% | 2945 |
|
|
2019
Q1 | $505K | Buy |
2,739
+41
| +2% | +$7.33K | ﹤0.01% | 2766 |
|
|
2018
Q4 | $482K | Hold |
2,698
| – | – | ﹤0.01% | 2783 |
|
|
2018
Q3 | $864K | Buy |
2,698
+184
| +7% | +$65.3K | ﹤0.01% | 2666 |
|
|
2018
Q2 | $1.01M | Hold |
2,514
| – | – | ﹤0.01% | 2583 |
|
|
2018
Q1 | $902K | Buy |
2,514
+260
| +12% | +$96.6K | ﹤0.01% | 2548 |
|
|
2017
Q4 | $894K | Buy |
2,254
+610
| +37% | +$252K | ﹤0.01% | 2542 |
|
|
2017
Q3 | $701K | Hold |
1,644
| – | – | ﹤0.01% | 2619 |
|
|
2017
Q2 | $264K | Buy |
+1,644
| New | +$224K | ﹤0.01% | 2916 |
|
|
2016
Q2 | – | Sell |
-585
| Closed | -$38K | – | 3105 |
|
|
2016
Q1 | $38K | Hold |
585
| – | – | ﹤0.01% | 3035 |
|
|
2015
Q4 | $50K | Hold |
585
| – | – | ﹤0.01% | 3072 |
|
|
2015
Q3 | $60K | Hold |
585
| – | – | ﹤0.01% | 3061 |
|
|
2015
Q2 | $74K | Buy |
+585
| New | +$87.9K | ﹤0.01% | 3061 |
|
Other funds holding ABEO
NCM
CCC
ACM
OIA
AIC
KCM
Charles Schwab's ABEO Position: Q2 2026 in Review
Charles Schwab reduced its Abeona Therapeutics (ABEO) stake by 5.2% in Q2 2026, selling an estimated $36.2K and leaving 120,514 shares worth $745K. The position accounts for ﹤0.01% of the portfolio, ranked #3108.
Charles Schwab first reported a position in ABEO in Q2 2015 and has held it in 32 quarters since. The position peaked at $1.01M in Q2 2018. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.
- Charles Schwab held 120,514 shares of Abeona Therapeutics worth $745K as of Q2 2026.
- Charles Schwab sold 6,595 Abeona Therapeutics shares in Q2 2026, an estimated $36.2K.
- Abeona Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3108 holding.
- Charles Schwab first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 32 quarters since.
- Charles Schwab's Abeona Therapeutics position peaked at $1.01M in Q2 2018.
- 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.